BioSyent Inc. (RX) Analysts See $0.09 EPS; Last Week Meridian Bancorp, Inc. (EBSB) Analysts

February 18, 2018 - By Peter Erickson

Analysts expect BioSyent Inc. (CVE:RX) to report $0.09 EPS on March, 21.They anticipate $0.01 EPS change or 12.50% from last quarter’s $0.08 EPS. V_RX’s profit would be $1.30 million giving it 24.17 P/E if the $0.09 EPS is correct. After having $0.09 EPS previously, BioSyent Inc.’s analysts see 0.00% EPS growth. The stock decreased 1.14% or $0.1 during the last trading session, reaching $8.7. About 2,408 shares traded. BioSyent Inc. (CVE:RX) has 0.00% since February 18, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 4 analysts covering Meridian Interstate Bancorp (NASDAQ:EBSB), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Meridian Interstate Bancorp had 11 analyst reports since September 30, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Tuesday, October 3 by Keefe Bruyette & Woods. The stock of Meridian Bancorp, Inc. (NASDAQ:EBSB) has “Market Perform” rating given on Wednesday, September 30 by Hovde Group. On Monday, June 26 the stock rating was upgraded by Compass Point to “Buy”. The firm has “Neutral” rating given on Friday, November 18 by Compass Point. Keefe Bruyette & Woods maintained the stock with “Hold” rating in Wednesday, January 24 report. Piper Jaffray maintained Meridian Bancorp, Inc. (NASDAQ:EBSB) rating on Tuesday, October 31. Piper Jaffray has “Hold” rating and $20.0 target. The rating was maintained by Piper Jaffray on Tuesday, July 25 with “Hold”. The stock has “Hold” rating by Keefe Bruyette & Woods on Thursday, December 21. The stock of Meridian Bancorp, Inc. (NASDAQ:EBSB) has “Hold” rating given on Thursday, August 31 by Keefe Bruyette & Woods. As per Wednesday, January 24, the company rating was maintained by Hovde Group. See Meridian Bancorp, Inc. (NASDAQ:EBSB) latest ratings:




24/01/2018 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $24.0 Maintain
24/01/2018 Broker: Hovde Group Rating: Hold New Target: $22.5 Maintain
21/12/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $24.5 Maintain
31/10/2017 Broker: Piper Jaffray Rating: Hold New Target: $20.0 Maintain
03/10/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $19.0 Maintain
31/08/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $19.0 Maintain

BioSyent Inc., a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally. The company has market cap of $126.11 million. The Company’s products include FeraMAX 150, an oral hematinic for the prevention and treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of papillary non-muscle invasive bladder cancer. It has a 26.28 P/E ratio. The company's products also comprise Cathejell Jelly 2% indicated for surface anesthesia and lubrication for various procedures, including male and female cystoscopies, catheterizations, and other endourethral operations; and endoscopies, proctoscopies, rectoscopies, and tracheal intubations, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis.

Meridian Bancorp, Inc. operates as the holding firm for East Boston Savings Bank that provides various financial services and products for individuals and businesses primarily in Suffolk, Norfolk, Middlesex, and Essex counties, Massachusetts. The company has market cap of $1.01 billion. The firm accepts various deposit products, such as non-interest-bearing demand deposits comprising checking accounts; interest-bearing demand accounts, including NOW and money market accounts; savings accounts; and certificates of deposits, as well as commercial checking accounts. It has a 25.3 P/E ratio. The Company’s loan portfolio consists of commercial real estate loans, which are secured by properties used for business purposes, such as office buildings, industrial facilities, and retail facilities; one- to four-family residential loans, including mortgage loans that enable borrowers to purchase or refinance existing homes; multi-family real estate loans; construction loans; commercial and industrial loans; home equity lines of credit; and consumer loans, including automobile loans, loans secured by passbook or certificate accounts, credit builder, and annuity and overdraft loans.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: